A3P Biomedical stock
A3P Biomedical är ett svenskt företag inom medicinsk diagnostik fokuserat på prostatacancer. De tar fram avancerade testmetoder för att erbjuda tidigare och mer precisa diagnoser vilket kan leda till bättre behandlingsresultat och minskade sjukvårdskostnader.
A3P Biomedical share price
Current bids and asks, the latest trade and A3P Biomedical's valuation. The full price history opens once you create an account.
Account required
See the full price history
Complete transaction history, order depth and valuation data are free once you open an account.
Create accountOther companies you may be interested in
Note: Share price is from each company's latest known share issue. The change compares it with the previous issue and does not account for splits or differing share classes.
A3P Biomedical new issues and valuations
| Date | Type | Share price | Valuation The company's valuation after the funding round was completed (Post-money). | Amount The specific amount raised in this funding round. |
|---|---|---|---|---|
| Q1 2026 | Share issuance | 17.21 SEK | SEK 883,872,177 | Locked |
| Q1 2026 | Share issuance | 16.64 SEK | SEK 849,868,812 | Locked |
| Q2 2022 | Share issuance | 23.83 SEK | SEK 1,213,500,000 | Locked |
See the amount raised in every funding round
Free · about two minutes
Note: Information on A3P Biomedical's funding rounds, amounts, and valuation is sourced from news media and public sources unless otherwise stated. Information on capital structure is sourced from public company registers unless otherwise stated.
Buy or sell A3P Biomedical shares
Place a bid or a sell order. Accumeo matches you with the counterparty and handles the transfer through an established process.
Create accountFree · about two minutes
Unsure about the price picture in A3P Biomedical, or sitting on a larger holding? Book fifteen minutes with the desk before you place an order.
Book a callReply within one business day
Have any questions about buying or selling shares in private companies? Don't hesitate to contact us.
How trading works
From account to completed transfer
1. Create an account
Identification is handled with BankID. The account is free and carries no obligation to trade.
2. Study the company
Price history, completed trades, ownership and documents gathered in one place.
3. Place your order
State the number of shares, the price and any conditions. Your order is anonymous to the market.
4. We handle settlement
On a match we draw up a share transfer agreement covering price, share count and closing date.
Settlement follows an established process with third-party verification of payment and share transfer, minimizing counterparty risk for both parties.
What an account unlocks
Every completed transaction in A3P Biomedical, with date and price per share.
The order book's price picture, updated in real time.
Largest owners, annual reports and issue terms.
A notice when new interest is registered or the price moves.
A3P Biomedical är ett svenskt företag inom medicinsk diagnostik fokuserat på prostatacancer. De tar fram avancerade testmetoder för att erbjuda tidigare och mer precisa diagnoser vilket kan leda till bättre behandlingsresultat och minskade sjukvårdskostnader.
Note: Information on A3P Biomedical is sourced from official channels and public sources unless otherwise stated.
Major Shareholders in A3P Biomedical
| Owner | Share |
|---|---|
| Henrik Grönberg | 25.65 % |
| Jan Martin Steinberg | 20.98 % |
| Ola Steinberg | 20.98 % |
| TomEnterprise Private AB | 10.10 % |
| Flerie Invest AB | 8.17 % |
Source: Bolagsverket (6/18/2026) · Information on A3P Biomedical's ownership structure is sourced from public company registers and external data providers unless otherwise stated.
A3P Biomedical key figures
| Key figures (SEK) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Income statement | |||
| Net sales | 18,453,000 | 15,610,000 | 10,315,000 |
| Operating result (EBIT) | – | – | – |
| EBITDA | -81,482,000 | -73,799,000 | -86,350,000 |
| Net profit for the year | -78,836,000 | -70,737,000 | -82,228,000 |
| Balance sheet | |||
| Total assets | 185,371,000 | 256,343,000 | 324,215,000 |
| Cash and bank | – | – | – |
| Current liabilities | 18,108,000 | 24,164,000 | 23,846,000 |
| Ratios | |||
| EBITDA margin | -441.6 % | -472.8 % | -837.1 % |
| Equity ratio | 84.2 % | 88.7 % | 91.7 % |
| Employees | 31 | 32 | 36 |
Figures come from the company's filed annual reports. Consolidated accounts are shown where they exist, otherwise the parent company.
Interested in A3P Biomedical shares?
Create an account to see completed trades and order depth, or call us if you would rather talk through the price picture first.
News about A3P Biomedical
Pioneering screening test offers potential to find more aggressive prostate cancers
Annals of Internal Medicine publishes study showing potential benefits of Stockholm3 in identifying patients with aggressive prostate cancer.
Stockholm3 upptäcker fler fall av aggressiv prostatacancer
Studie publicerad i Annals of Internal Medicine visar att Stockholm3 identifierar fler män med aggressiv prostatacancer
A3P ändrar i ledningen – medtechveteran tar över klubban
Christopher O´Connell tog plats i A3P:s styrelse under 2025, och tar nu över ordförandeklubban efter beslut vid bolagets årsstämma, enligt ett pressmeddelande. Han har mer än tre decenniers global ledarerfarenhet inom medicinteknik, life science och sjukvårdssektorn.
FAQ
A3P Biomedical is an unlisted company, meaning the shares are not traded on any exchange. Instead, transactions take place through direct transfers between parties, known as secondary trading, typically via a specialised platform for unlisted shares such as Accumeo. For larger international companies, investing through fund structures that pool several investors into a single ownership vehicle is also common. This allows smaller minimum investments and opens up access to international companies for non-institutional investors.
Yes, it is possible to buy existing shares in A3P Biomedical through secondary trading. On Accumeo you create a free account, submit an expression of interest with an amount and any conditions, and may then be matched with a seller. Once both parties have signed the customer agreement, a share transfer agreement is drawn up covering price, share count, and settlement date.
Yes, secondary trading is often the only realistic route to liquidity for an unlisted holding before an IPO or acquisition. Via Accumeo you submit an expression of interest with a share count and target price, and a match may be made with a potential buyer. The sale is executed through a share transfer agreement and registered either via Euroclear or directly in the company's share register, depending on how ownership is administered.
Unlisted companies have no continuous share price because there is no continuous exchange trading. The value is instead based on the latest secondary-market trade or on the price per share from the most recent share issuance. Accumeo shows both historical transaction prices and current bid/ask quotes, providing a combined reference point for pricing.
The value of an unlisted share is most often based on the latest trade — the price buyer and seller agreed in a transaction — or on the latest funding round, where the company and its investors agreed a price for the newly issued shares. These are the reference points shown on Accumeo's platform. It is, however, important to form your own view of value by examining the company's prospects. Financial reports, growth opportunities, market position, and comparable transactions in the sector all help to build a better picture of how the business may develop. Useful information can be found on the company's own website, via Accumeo's platform, and on services like allabolag.se.
No, A3P Biomedical is an unlisted company and its shares are not traded on the Stockholm Stock Exchange, NYSE, or any other regulated marketplace. Shares are instead traded through secondary trading between investors, typically via a specialised platform such as Accumeo.
Yes. Shares in A3P Biomedical can be delivered to an ordinary securities account with a broker such as Avanza or Nordnet, and are registered as the transaction completes.
We hold no registered transfer restrictions for A3P Biomedical. The articles of association are what decide this, so read them before placing an order — restrictions can be added without showing up in public sources.
Disclaimer: The information in this FAQ is provided for informational purposes only and does not constitute an offer to buy or sell securities, a solicitation of such an offer, or investment advice. Accumeo has no commercial relationship with the companies whose securities are mentioned. Independent advice should be obtained before making any investment decision.
Start exploring unlisted shares today
Join 5,000+ investors already trading unlisted shares. Create an account in 2 minutes with BankID — completely free.